Asset profile
ASC47
Small molecule
Evidence outlook · lead readout
NCT06427590 · Chronic Weight Management
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06427590: Participants were randomly assigned and the study was blinded against placebo, which is a solid design, but its focus was on side effects and blood tests rather than any weight or metabolic benefit, and enrollment was small. No results have been posted yet.
Covers the elevated-LDL-C cohort reported in the sponsor release; the trial's obese cohort is reported in a separate later data cut.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.